Clinical stage of breast cancer by parity, age at birth, and time since birth:: a progressive effect of pregnancy hormones?

被引:43
作者
Albrektsen, G
Heuch, I
Thoresen, S
Kvåle, G
机构
[1] Univ Bergen, Dept Math, N-5008 Bergen, Norway
[2] Univ Bergen, Ctr Int Hlth, N-5008 Bergen, Norway
[3] Canc Registry Norway, Oslo, Norway
关键词
D O I
10.1158/1055-9965.EPI-05-0634
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer diagnosed during pregnancy or 1 to 2 years after birth often occurs at a late stage. Little is known about tumor characteristics in the high-risk period shortly after a childbirth. We here explore whether stage of disease differs according to timing of births. Results are based on 22,351 Norwegian breast cancer patients of parity 0 to 5, ages 20 to 74 years. The proportion of stage II to IV tumors was considerably higher among parous than nulliparous women at age <30 years (52.7% versus 36.8%, P = 0.009), but similar or lower in other age groups (P-interaction = 0.029). In general, the largest proportion of stage II to IV tumors was found among women diagnosed during pregnancy or <2 years after birth. However, among women with late-age births (first or second birth >= 30 years, third birth >= 35 years), as well as women with an early second birth (<25 years), the proportion with advanced disease was rather similar or even higher among those diagnosed 2 to 6 years after birth (49.3-56.0%). The association between clinical stage and time since birth reached statistical significance among women with a late first or second birth and among all triparous women (P <= 0.032). The subgroups with a high proportion of advanced disease 2 to 6 years after birth corresponded quite well to those previously found to have the most pronounced transient increase in risk after birth. Thus, pregnancy hormones may have a progressive effect on breast cancer tumors in addition to a possible promoting effect. A potential effect of prolactinis discussed.
引用
收藏
页码:65 / 69
页数:5
相关论文
共 55 条
[1]   Breast cancer risk by age at birth, time since birth and time intervals between births:: exploring interaction effects [J].
Albrektsen, G ;
Heuch, I ;
Hansen, S ;
Kvåle, G .
BRITISH JOURNAL OF CANCER, 2005, 92 (01) :167-175
[2]  
Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
[3]   Is male breast cancer similar or different than female breast cancer? [J].
Anderson, WF ;
Althuis, MD ;
Brinton, LA ;
Devesa, SS .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (01) :77-86
[4]   Prolactin as an autocrine/paracrine growth factor in human cancer [J].
Ben-Jonathan, N ;
Liby, K ;
McFarland, M ;
Zinger, M .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (06) :245-250
[5]   Development of pure prolactin receptor antagonists [J].
Bernichtein, S ;
Kayser, C ;
Dillner, K ;
Moulin, S ;
Kopchick, JJ ;
Martial, JA ;
Norstedt, G ;
Isaksson, O ;
Kelly, PA ;
Goffin, V .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (38) :35988-35999
[6]   Prolactin as a local growth promoter in patients with breast cancer: GCRI experience [J].
Bhatavdekar, JM ;
Patel, DD ;
Shah, NG ;
Vora, HH ;
Suthar, TP ;
Ghosh, N ;
Chikhlikar, PR ;
Trivedi, TI .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000, 26 (06) :540-547
[7]   PLASMA PROLACTIN LEVELS AND AGE IN A FEMALE POPULATION - RELATION TO BREAST-CANCER [J].
BULBROOK, RD ;
WANG, DY ;
HAYWARD, JL ;
KWA, HG ;
CLETON, F .
INTERNATIONAL JOURNAL OF CANCER, 1981, 28 (01) :43-45
[8]   The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen [J].
Cameron, DA ;
Ritchie, AA ;
Miller, WR .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (12) :1545-1553
[9]   The role of prolactin in mammary carcinoma [J].
Clevenger, CV ;
Furth, PA ;
Hankinson, SE ;
Schuler, LA .
ENDOCRINE REVIEWS, 2003, 24 (01) :1-27
[10]   Risk factors for breast cancer according to estrogen and progesterone receptor status [J].
Colditz, GA ;
Rosner, BA ;
Chen, WY ;
Holmes, MD ;
Hankinson, SE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (03) :218-228